Italy Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Opportunity Analysis and Industry Forecast, 2023-2030

Italy Early Toxicity Testing Market

Industry:  Life Sciences & Healthcare | Publish Date: Aug 2023 | No of Pages:  93 | No. Tables:  83 | No. Figures:  32

Market Definition

The Italy Early Toxicity Testing Market was valued at USD 46.67 million in 2022 and is predicted to reach USD 100.09 million by 2030, with a CAGR of 8.61% from 2023 to 2030. Early toxicity testing serves as a crucial step in the evaluation of potential drugs, chemicals, or substances, aiming to detect and assess any harmful effects or toxicity during their initial stages of development. This assessment, usually carried out using in vitro methods or animal models, takes place before any experimentation on humans.

The primary goal of early toxicity testing is to promptly identify any safety concerns associated with a substance, enabling well-informed determinations regarding its viability for further advancement and subsequent trials. Engaging in early toxicity testing helps reduce the potential for harmful outcomes in both human participants and animals throughout clinical trials. This not only minimizes costs but also saves time in the broader course of drug development. This complex procedure involves a wide range of analyses and tests, including evaluations of cell viability, assessments of genotoxicity, and investigations into pharmacokinetics. 

The specific modalities employed are contingent on the intrinsic nature of the substance under scrutiny and its intended application. Recognized as an indispensable phase within the drug development journey, early toxicity testing profoundly bolsters the assurance of safety and efficacy for novel drugs and other substances, prior to their regulatory endorsement for human utilization.

Expanding Early Toxicity Testing Market in Italy Fuelled by Aging Population's Safety Needs

Growth of the early toxicity testing market in Italy is driven by rise in number of elderly people in the population, who require assurance of drug and chemical safety through early testing to prevent adverse reactions and ensure patient safety. For instance, according to the reports from the World Bank data, the percentage of people above the age of 65 in Italy reached 24% in 2021, as compared to 23% in 2020, and it is expected to increase in the coming years. With rapid growth in ageing population, need for safe medication with minimal or no long-term toxicology is increasing in the Country.

 

Increasing Prevalence of Chronic Diseases Spurs Demand for Novel Drugs and Therapies in Italy 

The rise in prevalence of chronic diseases such as cardiovascular, cancer, and diabetes in the country further propels the demand for new drugs and medication for treatment of these diseases. For instance, according to a report published by the World Health Organization (WHO), the major cause of death in Italy were chronic diseases such as cardiovascular and cancer in 2020, which is driving the demand for early detection and prevention of chronic diseases and emphasizing drug safety. Thus, it is expected to boost the growth of the Italy early toxicity testing market.

 

The Influence of Regulatory Limitations on the Growth of the Early Toxicity Testing Market in Italy

The stringent regulations set by regulatory bodies such as the US FDA and the EMA require extensive and rigorous testing for drug development and safety, which can be time-consuming and expensive and restrain growth of the market. The complexity and cost of complying with these regulations can pose a significant challenge for small and medium-sized companies that may not have the resources to carry out extensive testing.

As a result, some companies may choose to delay or abandon drug development projects, which can limit demand for early toxicity testing services. Moreover, stringent regulations can also result in a lengthy approval process for new drugs, further delaying the time it takes for drugs to reach the market. This, in turn, is expected to hamper growth of the market.

Technological Advancements in the field of Early Toxicity Testing Market in Italy

Introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period. Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. Traditional 2D cell culture models are limited in their ability to mimic complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing. 

However, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. 3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the market growth.

 

Competitive Landscape  

The Italy early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG., and Thermo Fisher Scientific Inc.

KEY BENEFITS

  • The Italy early toxicity testing market report provides a quantitative analysis of the market estimations throughout 2023-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep-dive analysis of the current and future Italy early toxicity testing market trends, depicting the prevalent investment pockets in the industry.

  • The information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report.

  • The competitive analysis of the key players along with their market share in the Italy Early Toxicity Testing industry, is mentioned.

  • The SWOT analysis and Porter’s Five Forces model are elaborated on in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

ITALY EARLY TOXICITY TESTING MARKET KEY SEGMENTS

By Technique

  • In Vivo

  • In Vitro

    • Cell Culture    

    • PCR    

    • ELISA    

    • Western Blotting    

    • Protein Binding Assays    

  • In Silico    

By Toxicity Endpoint

  • Genotoxicity    

  • Dermal Toxicity 

  • Skin Toxicity 

  • Ocular Toxicity    

  • Phototoxicity    

  • Others    

By End User

  • Pharmaceutical Industry    

  • Cosmetic Industry    

  • Chemical Industry    

  • Food Industry     

  • Others

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2022

USD 46.67 Million

Revenue Forecast in 2030

USD 100.09 Million

Growth Rate

CAGR of 8.61% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Million (USD)

Growth Factors

The growing incidence of chronic illnesses.

Technological advancement.

Companies Profiled

15

Market Share

Available for 15 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2       ITALY EARLY TOXICITY TESTING MARKET BY TECHNIQUE

           2.1      OVERVIEW

           2.2      IN VIVO MARKET

           2.3      IN VITRO MARKET

                         2.3.1      CELL CULTURE

                         2.3.2      PCR

                         2.3.3      ELISA

                         2.3.4      WESTERN BLOTTING

                         2.3.5      PROTEIN BINDING ASSAYS

           2.4      IN SILICO MARKET

3       ITALY EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT

           3.1      OVERVIEW

           3.2      GENOTOXICITY MARKET

           3.3      DERMAL TOXICITY MARKET

           3.4      SKIN TOXICITY MARKET

           3.5      OCULAR TOXICITY MARKET

           3.6      PHOTOTOXICITY MARKET

           3.7      OTHERS MARKET

4       ITALY EARLY TOXICITY TESTING MARKET BY END USER

           4.1      OVERVIEW

           4.2      PHARMACEUTICAL INDUSTRY MARKET

           4.3      COSMETIC INDUSTRY MARKET

           4.4      CHEMICAL INDUSTRY MARKET

           4.5      FOOD INDUSTRY MARKET

           4.6      OTHERS MARKET

5      COMPANY PROFILES

           5.1     INOTIV INC.

                         5.1.1     COMPANY OVERVIEW

                         5.1.2     COMPANY SNAPSHOT

                         5.1.3     OPERATING BUSINESS SEGMENTS

                         5.1.4     PRODUCT PORTFOLIO

                         5.1.5     BUSINESS PERFORMANCE

                         5.1.6     BUSINESS SEGMENTS

                         5.1.7     GEOGRAPHIC SEGMENTS

                         5.1.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.1.9     PRIMARY MARKET COMPETITORS

           5.2     BIO-RAD LABORATORIES INC

                         5.2.1     COMPANY OVERVIEW

                         5.2.2     COMPANY SNAPSHOT

                         5.2.3     OPERATING BUSINESS SEGMENTS

                         5.2.4     PRODUCT PORTFOLIO

                         5.2.5     BUSINESS PERFORMANCE

                         5.2.6     BUSINESS SEGMENTS

                         5.2.7     GEOGRAPHIC SEGMENTS

                         5.2.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.2.9     PRIMARY MARKET COMPETITORS

           5.3     EVOTEC A.G.

                         5.3.1     COMPANY OVERVIEW

                         5.3.2     COMPANY SNAPSHOT

                         5.3.3     OPERATING BUSINESS SEGMENTS

                         5.3.4     PRODUCT PORTFOLIO

                         5.3.5     BUSINESS PERFORMANCE

                         5.3.6     BUSINESS SEGMENTS

                         5.3.7     GEOGRAPHIC SEGMENTS

                         5.3.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.3.9     PRIMARY MARKET COMPETITORS

           5.4     AGILENT TECHNOLOGIES INC

                         5.4.1     COMPANY OVERVIEW

                         5.4.2     COMPANY SNAPSHOT

                         5.4.3     OPERATING BUSINESS SEGMENTS

                         5.4.4     PRODUCT PORTFOLIO

                         5.4.5     BUSINESS PERFORMANCE

                         5.4.6     BUSINESS SEGMENTS

                         5.4.7     GEOGRAPHIC SEGMENTS

                         5.4.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.4.9     PRIMARY MARKET COMPETITORS

           5.5     WUXI APPTEC

                         5.5.1     COMPANY OVERVIEW

                         5.5.2     COMPANY SNAPSHOT

                         5.5.3     OPERATING BUSINESS SEGMENTS

                         5.5.4     PRODUCT PORTFOLIO

                         5.5.5     BUSINESS PERFORMANCE

                         5.5.6     BUSINESS SEGMENTS

                         5.5.7     GEOGRAPHIC SEGMENTS

                         5.5.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.5.9     PRIMARY MARKET COMPETITORS

           5.6     BRUKER

                         5.6.1     COMPANY OVERVIEW

                         5.6.2     COMPANY SNAPSHOT

                         5.6.3     OPERATING BUSINESS SEGMENTS

                         5.6.4     PRODUCT PORTFOLIO

                         5.6.5     BUSINESS PERFORMANCE

                         5.6.6     BUSINESS SEGMENTS

                         5.6.7     GEOGRAPHIC SEGMENTS

                         5.6.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.6.9     PRIMARY MARKET COMPETITORS

           5.7     PERKINELMER INC.

                         5.7.1     COMPANY OVERVIEW

                         5.7.2     COMPANY SNAPSHOT

                         5.7.3     OPERATING BUSINESS SEGMENTS

                         5.7.4     PRODUCT PORTFOLIO

                         5.7.5     BUSINESS PERFORMANCE

                         5.7.6     BUSINESS SEGMENTS

                         5.7.7     GEOGRAPHIC SEGMENTS

                         5.7.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.7.9     PRIMARY MARKET COMPETITORS

           5.8     ENZO BIOCHEM INC.

                         5.8.1     COMPANY OVERVIEW

                         5.8.2     COMPANY SNAPSHOT

                         5.8.3     OPERATING BUSINESS SEGMENTS

                         5.8.4     PRODUCT PORTFOLIO

                         5.8.5     BUSINESS PERFORMANCE

                         5.8.6     BUSINESS SEGMENTS

                         5.8.7     GEOGRAPHIC SEGMENTS

                         5.8.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.8.9     PRIMARY MARKET COMPETITORS

           5.9     DANAHER CORPORATION

                         5.9.1     COMPANY OVERVIEW

                         5.9.2     COMPANY SNAPSHOT

                         5.9.3     OPERATING BUSINESS SEGMENTS

                         5.9.4     PRODUCT PORTFOLIO

                         5.9.5     BUSINESS PERFORMANCE

                         5.9.6     BUSINESS SEGMENTS

                         5.9.7     GEOGRAPHIC SEGMENTS

                         5.9.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.9.9     PRIMARY MARKET COMPETITORS

           5.10     EUROFINS SCIENTIFIC SE

                         5.10.1     COMPANY OVERVIEW

                         5.10.2     COMPANY SNAPSHOT

                         5.10.3     OPERATING BUSINESS SEGMENTS

                         5.10.4     PRODUCT PORTFOLIO

                         5.10.5     BUSINESS PERFORMANCE

                         5.10.6     BUSINESS SEGMENTS

                         5.10.7     GEOGRAPHIC SEGMENTS

                         5.10.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.10.9     PRIMARY MARKET COMPETITORS

           5.11     CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

                         5.11.1     COMPANY OVERVIEW

                         5.11.2     COMPANY SNAPSHOT

                         5.11.3     OPERATING BUSINESS SEGMENTS

                         5.11.4     PRODUCT PORTFOLIO

                         5.11.5     BUSINESS PERFORMANCE

                         5.11.6     BUSINESS SEGMENTS

                         5.11.7     GEOGRAPHIC SEGMENTS

                         5.11.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.11.9     PRIMARY MARKET COMPETITORS

           5.12     LABCORP DRUG DEVELOPMENT.

                         5.12.1     COMPANY OVERVIEW

                         5.12.2     COMPANY SNAPSHOT

                         5.12.3     OPERATING BUSINESS SEGMENTS

                         5.12.4     PRODUCT PORTFOLIO

                         5.12.5     BUSINESS PERFORMANCE

                         5.12.6     BUSINESS SEGMENTS

                         5.12.7     GEOGRAPHIC SEGMENTS

                         5.12.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.12.9     PRIMARY MARKET COMPETITORS

           5.13     PROMEGA CORPORATION

                         5.13.1     COMPANY OVERVIEW

                         5.13.2     COMPANY SNAPSHOT

                         5.13.3     OPERATING BUSINESS SEGMENTS

                         5.13.4     PRODUCT PORTFOLIO

                         5.13.5     BUSINESS PERFORMANCE

                         5.13.6     BUSINESS SEGMENTS

                         5.13.7     GEOGRAPHIC SEGMENTS

                         5.13.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.13.9     PRIMARY MARKET COMPETITORS

           5.14     INSPHERO AG

                         5.14.1     COMPANY OVERVIEW

                         5.14.2     COMPANY SNAPSHOT

                         5.14.3     OPERATING BUSINESS SEGMENTS

                         5.14.4     PRODUCT PORTFOLIO

                         5.14.5     BUSINESS PERFORMANCE

                         5.14.6     BUSINESS SEGMENTS

                         5.14.7     GEOGRAPHIC SEGMENTS

                         5.14.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.14.9     PRIMARY MARKET COMPETITORS

           5.15     THERMO FISHER SCIENTIFIC INC.

                         5.15.1     COMPANY OVERVIEW

                         5.15.2     COMPANY SNAPSHOT

                         5.15.3     OPERATING BUSINESS SEGMENTS

                         5.15.4     PRODUCT PORTFOLIO

                         5.15.5     BUSINESS PERFORMANCE

                         5.15.6     BUSINESS SEGMENTS

                         5.15.7     GEOGRAPHIC SEGMENTS

                         5.15.8     KEY STRATEGIC MOVES AND DEVELOPMENT

                         5.15.9     PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 2. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 3. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 4. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 5. INOTIV INC.: COMPANY SNAPSHOT

TABLE 6. INOTIV INC: OPERATING SEGMENTS

TABLE 7. INOTIV INC.: PR0DUCT PORTFOLIO

TABLE 8. INOTIV INC.: BUSINESS SEGMENT

TABLE 9. INOTIV INC.: GEOGRAPHIC SEGMENT

TABLE 10. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 11. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 12. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 13. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 14. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT

TABLE 15. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT

TABLE 16. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 17. EVOTEC A.G.: COMPANY SNAPSHOT

TABLE 18. EVOTEC A.G.: OPERATING SEGMENTS

TABLE 19. EVOTEC A.G.: PRODUCT PORTFOLIO

TABLE 20. EVOTEC A.G.: BUSINESS SEGMENT

TABLE 21. EVOTEC A.G.: GEOGRAPHIC SEGMENT

TABLE 22. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 23. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 24. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 25. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 26. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT

TABLE 27. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT

TABLE 28. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 29. WUXI APPTEC.: COMPANY SNAPSHOT

TABLE 30. WUXI APPTEC: OPERATING SEGMENTS

TABLE 31. WUXI APPTEC.: PR0DUCT PORTFOLIO

TABLE 32. WUXI APPTEC.: BUSINESS SEGMENT

TABLE 33. WUXI APPTEC.: GEOGRAPHIC SEGMENT

TABLE 34. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 35. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 36. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 37. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 38. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 39. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 40. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 41. BRUKER: COMPANY SNAPSHOT

TABLE 42. BRUKER: OPERATING SEGMENTS

TABLE 43. BRUKER: PRODUCT PORTFOLIO

TABLE 44. BRUKER: BUSINESS SEGMENT

TABLE 45. BRUKER: GEOGRAPHIC SEGMENT

TABLE 46. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 47. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 48. PERKINELMER INC.: OPERATING SEGMENTS

TABLE 49. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 50. PERKINELMER INC.: BUSINESS SEGMENT

TABLE 51. PERKINELMER INC.: GEOGRAPHIC SEGMENT

TABLE 52. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 53. ENZO BIOCHEM INC.: COMPANY SNAPSHOT

TABLE 54. ENZO BIOCHEM INC.: OPERATING SEGMENTS

TABLE 55. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO

TABLE 56. ENZO BIOCHEM INC.: BUSINESS SEGMENT

TABLE 57. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT

TABLE 58. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 59. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 60. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 61. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 62. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 63. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 64. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT

TABLE 65. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO

TABLE 66. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT

TABLE 67. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 68. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT

TABLE 69. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS

TABLE 70. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO

TABLE 71. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT

TABLE 72. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT

TABLE 73. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 74. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT

TABLE 75. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS

TABLE 76. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO

TABLE 77. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT

TABLE 78. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT

TABLE 79. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 80. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 81. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 82. INSPHERO AG: COMPANY SNAPSHOT

TABLE 83. INSPHERO AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 2. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 3. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 4. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 5. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 6. INOTIV INC: PRIMARY MARKET COMPETITORS

FIGURE 7. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 8. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS

FIGURE 9. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)

FIGURE 10. EVOTEC A.G.: PRIMARY MARKET COMPETITORS

FIGURE 11. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)

FIGURE 12. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS

FIGURE 13. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 14. WUXI APPTEC: PRIMARY MARKET COMPETITORS

FIGURE 15. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 16. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 17. BRUKER: NET SALES, 2019–2021 ($MILLION)

FIGURE 18. BRUKER: PRIMARY MARKET COMPETITORS

FIGURE 19. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 20. PERKINELMER INC.: PRIMARY MARKET COMPETITORS

FIGURE 21. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 22. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS

FIGURE 23. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 24. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 25. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 26. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS

FIGURE 27. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 28. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS

FIGURE 29. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 30. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS

FIGURE 31. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 32. INSPHERO AG: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Inotiv Inc.

  • Bio-Rad Laboratories Inc

  • Evotec A.G. 

  • Agilent Technologies Inc

  • Wuxi Apptec

  • Bruker

  • Perkinelmer Inc.

  • Enzo Biochem Inc.

  • Danaher Corporation

  • Eurofins Scientific SE

  • Charles River Laboratories International, Inc.

  • Labcorp Drug Development.

  • Promega Corporation

  • Insphero AG

  • Thermo Fisher Scientific Inc.


Frequently Asked Questions
What will be the worth of Italy early toxicity testing market by the end of 2030?

According to the report published by the Next Move Consulting, the Italy early toxicity testing market business is expected to hit at $100.09 million (USD) by 2030.

What are the leading companies in the Italy early toxicity testing market?

The Italy early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG, and Thermo Fisher Scientific Inc.

What are the market segmentations and scope of the study for the Italy early toxicity testing industry?

The Italy early toxicity testing market share is segmented on the basis of technique, toxicity endpoint, and end user.

What factors are driving the growth of the Italy early toxicity testing market?

The expansion of the early toxicity testing market in Italy is propelled by factors such as the safety requirements of an aging population, the growing incidence of chronic illnesses, and advancements in technology.

What factors are limiting the growth of the Italy early toxicity testing market?

The factors limiting the growth of the Italy early toxicity testing market are stringent regulations and lack of expertise.